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Dear editor
We read with great interest the recent paper by Braeken et al which analyzed the 
associations between COPD and community-acquired pneumonia (CAP), published 
in your journal.1 In this large population-based study, the authors have concluded that 
the risk of CAP increases fourfold in patients with COPD, independent of smoking 
status. The authors briefly discuss potential smoking-induced mechanisms leading to 
increased risk of CAP in COPD, such as host physiological and structural changes, 
increased bacterial virulence and impaired host immunity. The authors also stress 
the need for further mechanistic studies on the cause of this increased risk of CAP in 
COPD patients.1
We believe that some of our recent work is relevant to these findings. We have 
published several studies that have found increased respiratory tract epithelial expres-
sion of specific bacterial adhesion factors in COPD, in particular platelet-activating 
factor receptor (PAFr) which is the major pneumococcal and Haemophilus influenzae 
adhesion molecule.2,3 This could well be one important mechanism that the authors 
did not mention that could significantly increase the risk of Streptococcus pneumoniae 
respiratory infection in COPD. Pack-years of smoking were strongly related to 
epithelial PAFr protein levels in COPD patients.2 Notably, S. pneumoniae expresses 
phosphorylcholine in its cell wall that specifically binds to PAFr, leading to initial 
attachment and subsequent translocation of bacteria into deeper tissue.
In addition, cultured respiratory epithelial cells exposed to cigarette smoke extract 
exhibited significantly increased PAFr protein expression and greater S. pneumoniae 
adhesion. Notably, blocking PAFr by specific PAFr-antagonist (WEB-2086) reduced 
adherence of S. pneumoniae to the levels seen in control cells.4 This opens the 
possibility that PAFr could be targeted therapeutically in COPD patients to limit 
chronic bacterial adhesion and potentially acute exacerbations, but also CAP in this 
vulnerable population.
Translational research in this area of bacterial–epithelial interactions is still in its 
infancy but has huge potential to provide novel insights into COPD pathogenesis and 
its natural history, as well as new therapeutic targets. Blocking the initial stages of 
bacterial adhesion and colonization in already activated epithelium in COPD patients 
could emerge as a promising target for the development of alternate, non-antibiotic 
pharmacotherapies for the management of the disease and its infective complication.5 
Preliminary data in both in vitro and in vivo models is so promising that further clinical 
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research on anti-PAFr therapies is now warranted to ascertain 
their efficacy in preventing and treating bacterial infections 
in COPD. There may be broader application to other 
chronic respiratory diseases, such cystic fibrosis, given that 
Pseudomonas aeruginosa is the third “common respiratory 
pathogen” that also adheres to PAFr. Indeed, there seems 
to be no other obvious mechanism that links these three 
quite disparate organisms, making them so dangerous to the 
respiratory tract in very particular circumstances.
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Dear editor
We would like to thank Shukla et al for their interesting and 
valuable addition to our study, which showed that the risk 
of community-acquired pneumonia (CAP) was fourfold 
increased among patients with COPD, regardless of their 
smoking status.1 They first speculate that their observation of 
expression of adhesion molecules (PAFr) in several bacteria 
that can cause CAP among COPD patients may explain our 
findings. Although they observed a significantly increased 
expression of PAFr among smokers with COPD versus 
smokers with a normal lung function, PAFr expression was 
not elevated among COPD patients who were ex-smokers.2 
Thus, these observations are not supportive of the fourfold 
increased risk of CAP among patients with COPD regardless 
of their smoking status.2 Also, they are not in line with another 
study by the same group4 in which there was no difference in 
in vivo expression of PAFr between current- and ex-smoking 
COPD patients. It should also be noted that there is limited 
comparability between both study populations: while non-
small-cell lung cancer was an inclusion criterion in the 
study by Shukla et al,2 we evaluated COPD and non-COPD 
patients from the general population, and only 13%–14% had 
a history of any malignancy, excluding non-melanoma skin 
cancer.2 The hypothesis by Shukla et al is also not supported 
by their observation that a 6-month intervention with inhaled 
corticosteroids (ICS) did not affect PAFr expression, while 
ICS use is a well-established risk factor of CAP in patients 
with COPD.3,4 Thus, while the hypothesis is interesting, 
it certainly requires more and larger clinical studies.
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